Overview
- A federal class action titled Mazzarino v. ADMA Biologics is pending in the U.S. District Court for the District of New Jersey and law firms are soliciting investors to join the case.
- The filing asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act and draws on a Culper Research short report that accuses ADMA of booking sales that were not driven by end‑user demand.
- The complaint cites an alleged scheme in which ADMA offered rebates and extended payment terms to a distributor to induce excess purchases, a practice commonly called channel stuffing.
- ADMA’s share price fell sharply after the short report and analyst downgrades, with multi‑day drops that plaintiffs say caused investor losses and prompted the lawsuit.
- Investors have been told they may seek lead‑plaintiff status by August 10, 2026, and the case could move to competing lead‑plaintiff motions, early discovery, dismissal motions, or settlement depending on what emerges in litigation.